🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to researchers.

An International Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million infections each year. Especially elevated rates are seen in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The trial involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have expressed positive views. Access to a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is considered crucial to lessen the impact of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.